Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis (MYCOGENIE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03349931|
Recruitment Status : Recruiting
First Posted : November 22, 2017
Last Update Posted : May 1, 2018
|Condition or disease||Intervention/treatment|
|Invasive Aspergillosis in Patients With Onco-haematological Diseases||Diagnostic Test: DNA extraction and detection of Aspergillus fumigatus in serum samples|
Accurate diagnosis of invasive pulmonary aspergillosis (IPA) in patients at high risk of invasive fungal infection remains challenging due to difficulties in differentiating IPA from pulmonary infections caused by other molds or bacteria on clinical and radiological grounds. Therefore, culture-based microbiological diagnosis is of primary importance but requires semi-invasive or invasive procedures, such as bronchoalveolar Lavage (BAL) or computed-tomography (CT)-guided needle biopsy.
Alternate diagnostic methods include the detection of biomarkers, such as fungal antigens (Aspergillus galactomannan [GM]) or DNA released by Aspergillus hyphae in host tissues. These biomarkers are well recognized as early IPA predictors Recently, several clinical evaluations to detect Aspergillus DNA, either in respiratory or in blood-based samples, have clearly shown the diagnostic value of this biomarker. In addition, methodological recommendations have been established for PCR protocols, and different standardized Aspergillus quantitative PCR (qPCR) kits have been commercialized. These recent advances show that PCR is now mature for routine use in clinical settings.
Another issue is the emergence of aspergillosis due to azole-resistant isolates. Acquired azole resistance in A. fumigatus has been reported since 1997 and has emerged in many countries, particularly in Europe, as well as on other continents. In some instances, acquired resistance may be driven by antifungal selection in patients receiving long-term therapy. Nevertheless, it seems that many azole-resistant strains originated in the environment due to selection by azole fungicides used in agriculture. Azole resistance in A. fumigatus is associated mainly with mutations in the cyp51A gene, and among several mutations described, the most frequent is the mutation comprising a 34-bp tandem repeat (TR34) and the L98H alteration. Since azoles are the recommended first-line treatment for IPA, the emergence of azole resistance is worrisome and has been shown to be associated with an increased rate of clinical failure. For these reasons, routine antifungal susceptibility testing of clinical isolates has been recommended recently. Nevertheless, isolates are not always retrieved in culture, particularly for patients with hematological malignancies. Therefore, molecular detection of resistance may be a major advance for the management of patients with invasive aspergillosis.
The aim of this study will be to validate the new MycoGENIE A. fumigatus real-time PCR kit and to evaluate its performance on clinical samples for the detection of A. fumigatus and its azole resistance. This multiplex assay detects DNA from the A. fumigatus species complex by targeting the multicopy 28S rRNA gene and specific TR34 and L98H mutations in the single-copy number cyp51A gene of A. fumigatus.
The study will be performed in hematological patients with high-risk of developping IA during the course of chemotherapy. In these patients, bi-weekly detection of GM is routinely performed in all centers in France. The PCR will be performed on the samples used for GM detection. DNA will be extracted according to the manufacturer's protocol, using the MycoGENIE kit for AutoMag solution. Real-time PCR for the detection of A. fumigatus DNA will be performed using the MycoGENIE A. fumigatus real-time PCR kit (Ademtech, Pessac, France).
AI will be defined as proven or probable aspergillosis, according to EORTC criteria.
For each patient, clinical data will be collected in each center. These data include: EORTC classification, type and duration of antifungal treatments, results of GM tests, results of mycological cultures, and results of PCR tests (positivity and Ct values). For each patient a case report form (CRF) will be filled and transfered to the investigating center for analysis. Sensitivity, specificity, PPV and NPV of the PCR test will be calculated.
|Study Type :||Observational|
|Estimated Enrollment :||420 participants|
|Official Title:||Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients|
|Actual Study Start Date :||February 5, 2018|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||April 2019|
Hematological patients at high risk for invasive aspergillosis
Diagnostic Test: DNA extraction and detection of Aspergillus fumigatus in serum samples
Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
- Performance of PCR for Aspergillosis diagnosis [ Time Frame: 6 months ]Determination of the performances (Sensitivity, specificity, PPV and NPV) of the kit
- Detection of azole resistance [ Time Frame: 6 months ]Detection of TR34 and L98H mutations in the A. fumigatus single-copy number gene cyp51A.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03349931
|Contact: Marie-Elisabeth BOUGNOUX, MD, PhD||+33 (0)1 44 49 25 email@example.com|
|Contact: PRISSILE BAKOUBOULA, PhD||+33 (0)1 71 19 64 firstname.lastname@example.org|
|CHU Bordeaux, Groupe hospitalier||Recruiting|
|Bordeaux, France, 33000|
|Contact: Claire CALMETTES +33 (0)5 57 65 65 11 email@example.com|
|Principal Investigator: Claire CALMETTES, MD, PhD|
|Principal Investigator: Isabelle ACCOCEBERRY, MD, PhD|
|Principal Investigator: Noémie CORON, MD, PhD|
|CHU de DIJON, Hôpital du bocage||Recruiting|
|Dijon, France, 21000|
|Contact: Denis CAILLOT +33 (0)3 80 29 36 45 firstname.lastname@example.org|
|Principal Investigator: Denis CAILLOT, MD, PhD|
|Principal Investigator: Frederic DALLE, MD, PhD|
|CHRU de Lille, Hôpital Claude Huriez||Recruiting|
|Lille, France, 59000|
|Contact: Ibrahim Yakoub-Agha +33 (0)3 20 44 55 51 email@example.com|
|Principal Investigator: Ibrahim Yakoub-Agha, MD, PhD|
|Principal Investigator: Séverine Loridant, MD, PhD|
|CHU de Nantes, Hôpital de Moncousu||Recruiting|
|Nantes, France, 44000|
|Contact: Thomas GASTINNE +33 (0)2 40 08 33 02 firstname.lastname@example.org|
|Principal Investigator: Thomas GASTINNE, MD, PhD|
|Principal Investigator: Patrice LE PAPE, MD, PhD|
|Hôpital Necker - Enfants maladies (AP-HP)||Recruiting|
|Paris, France, 75015|
|Contact: Marie-Elizabeth BOUGNOUX, MD, PhD +33 (0)1 44 49 25 45 email@example.com|
|Principal Investigator: Marie-Elisabeth BOUGNOUX, MD, PhD|
|Principal Investigator: Felipe SUAREZ, MD, PhD|
|CHU de RENNES, hôpital de Pontchaillou||Recruiting|
|Rennes, France, 35000|
|Contact: Laure GOURSAUD +33 (0)2 99 28 57 45 firstname.lastname@example.org|
|Principal Investigator: Laure GOURSAUD, MD, PhD|
|Principal Investigator: Jean-Pierre GANGNEUX, MD, PhD|
|Principal Investigator:||Eric DANNAOUI, MD, PhD||Assistance Publique - Hôpitaux de Paris|
|Principal Investigator:||Marie-Elisabeth BOUGNOUX, MD, PhD||Assistance Publique - Hôpitaux de Paris|